The present study investigated the anti-angiogenic effects of TSAJ on VEGF-induced angiogenesis in vitro and in vivo, in order to explore the potential for TSAJ as an anti-tumor drug targeting the VEGF/VEGFR2 signaling pathway. Here, KDR is linked to neoplasm.